Analysis shows AstraZeneca's exenatide has favorable tolerability profile

15 September 2015

Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced that analysis of its type 2 diabetes drug exenatide once weekly showed a favorable gastrointestinal tolerability profile compared to several other agents.

Exenatide, marketed under the trade name Bydureon, performed more tolerably than shorter-acting glucagon-like peptide-1 receptor agonists (GLP-1RA), exenatide twice daily (ExBID) and liraglutide once daily (LiraQD). These results were presented today at the 51st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden.

Intent-to-treat analyses were conducted to evaluate differences in gastrointestinal tolerability with short- and long-acting GLP-1RAs, using pooled data from three studies comparing ExQW to ExBID and data from the DURATION-6 trial which compared ExQW to LiraQD.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK